Evelo Biosciences Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evelo Biosciences stock.
View analyst ratings for Evelo Biosciences or view top-rated stocks.

Wall Street analysts have given Evelo Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evelo Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Evelo Biosciences.

Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings data on Wednesday, July, 28th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.01.
View Evelo Biosciences' earnings history.

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVLO shares have increased by 90.8% and is now trading at $8.34.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1 year price objectives for Evelo Biosciences' stock. Their forecasts range from $12.00 to $38.00. On average, they anticipate Evelo Biosciences' share price to reach $21.80 in the next year. This suggests a possible upside of 161.4% from the stock's current price.
View analysts' price targets for Evelo Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Evelo Biosciences include Generation Bio (GBIO), Amneal Pharmaceuticals (AMRX), Kadmon (KDMN), Tango Therapeutics (TNGX), Supernus Pharmaceuticals (SUPN), Day One Biopharmaceuticals (DAWN), Arcturus Therapeutics (ARCT), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), Aerpio Pharmaceuticals (ARPO), Zealand Pharma A/S (ZEAL), Kura Oncology (KURA), COMPASS Pathways (CMPS), Vectura Group (VEGPF) and Kronos Bio (KRON).
View all of EVLO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

Evelo Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), Credit Suisse AG (5.80%), BlackRock Inc. (3.45%), Vanguard Group Inc. (2.77%), State Street Corp (0.92%) and Geode Capital Management LLC (0.88%). Company insiders that own Evelo Biosciences stock include David R Epstein, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu.
View institutional ownership trends for Evelo Biosciences.

EVLO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Millennium Management LLC, JPMorgan Chase & Co., AQR Capital Management LLC, Bank of America Corp DE, Citadel Advisors LLC, and Morgan Stanley.
View insider buying and selling activity for Evelo Biosciences or view top insider-selling stocks.

EVLO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Northern Trust Corp, Nuveen Asset Management LLC, and Alberta Investment Management Corp. Company insiders that have bought Evelo Biosciences stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Evelo Biosciences or or view top insider-buying stocks.

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVLO stock can currently be purchased for approximately $8.34.

Evelo Biosciences has a market capitalization of $445.36 million. The company earns $-93,670,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

Evelo Biosciences employs 2,018 workers across the globe.

The official website for Evelo Biosciences is www.evelobio.com.

Evelo Biosciences is headquartered at 620 Memorial Drive Suite 500 West, Cambridge MA, 02139.

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at (617) 577-0300 or via email at [email protected].